glp 1 therapy for diabetes WHO Endorses GLP‑1 Obesity Care: Implications Providers GLP-1 Medications Infographic | Medidex
Description
Multivariate analysis of 12-month HbA1c reported that HbA1c significantly increased after cessation of liraglutide in the liraglutide group by ~10.9 mmol/mol when compared to placebo (10.9 mmol/mol, 95%CI: 1.1, 20.6 mmol/mol, p = 0.032, Supplementary Table 5.4)
Only specific oral formulations with absorption enhancers were tested and approved
The precise mechanism of activating the proliferative pathway via the PI3-kinase pathway is not clear
I know everyone is going to compare the two but its really not an apples to apples comparison
